CERC:NSD-Cerecor Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 2.58

Change

+0.08 (+3.20)%

Market Cap

USD 0.19B

Volume

0.36M

Average Target Price

USD 10.00 (+287.60%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Cerecor Inc., a biopharmaceutical company, focuses on development and commercialization of treatments for rare pediatric and orphan diseases. It develop therapies for the treatment of inherited metabolic disorders, such as CERC-801 and CERC-802, which completed the phase I clinical trial; and CERC-803. The company is also involved in the developing of CERC-007, an anti-IL-18 monoclonal antibody for the treatment of autoimmune inflammatory diseases, such as adult onset stills disease and multiple myeloma; CERC-006, a dual mTOR inhibitor to treat complex lymphatic malformations; and CERC-002, an anti-LIGHT monoclonal antibody for the treatment of Pediatric-onset Crohn's diseases. In addition, it develops CERC-913, a protide nucleotide for the treatment of mitochondrial disorder; CERC-005, a monoclonal antibody to treat rare auto-inflammatory diseases; CERC-301 for the treatment of symptomatic Orthostatic Hypotension; and CERC-406 for the treatment of Parkinson's disease. Further, the company offers Millipred, an oral prednisolone for the treatment of inflammatory conditions, such as arthritis, blood disorders, immune system disorders, skin and eye conditions, respiratory disorders, cancer, and severe allergies. The company was formerly known as Ceregen Corporation and changed its name to Cerecor Inc. in March 2011. Cerecor Inc. was founded in 2011 and is headquartered in Rockville, Maryland.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-12-01 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

-11.73 (-7.68%)

USD60.44B N/A N/A
VRTX Vertex Pharmaceuticals Incorpo..

+2.55 (+1.12%)

USD59.22B 22.32 17.39
REGN Regeneron Pharmaceuticals, Inc

-1.96 (-0.38%)

USD55.06B 18.91 14.53
SGEN Seagen Inc

+7.10 (+4.17%)

USD30.48B 64.32 62.62
BNTX BioNTech SE

-10.23 (-8.23%)

USD29.92B -99,999.99 N/A
ALXN Alexion Pharmaceuticals, Inc

+0.04 (+0.03%)

USD26.72B 28.34 26.92
RPRX Royalty Pharma plc

+0.18 (+0.42%)

USD26.64B 22.60 9.74
GMAB Genmab A/S

-0.37 (-0.96%)

USD25.29B 26.59 2.61
BGNE BeiGene, Ltd

-9.20 (-3.60%)

USD21.65B N/A N/A
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing CERC

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -52.13% 14% F 6% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -52.13% 14% F 6% F
Trailing 12 Months  
Capital Gain -27.32% 25% F 16% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -27.32% 25% F 15% F
Trailing 5 Years  
Capital Gain -29.12% 50% F 25% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -29.12% 49% F 23% F
Average Annual (5 Year Horizon)  
Capital Gain 90.11% N/A N/A 96% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 90.11% N/A N/A 96% A
Risk Return Profile  
Volatility (Standard Deviation) 230.99% N/A N/A 4% F
Risk Adjusted Return 39.01% N/A N/A 61% D-
Market Capitalization 0.19B 40% F 38% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 141.30 8% F 9% F
Price/Book Ratio 4.98 43% F 28% F
Price / Cash Flow Ratio -9.95 63% D 79% C+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -189.74% 13% F 5% F
Return on Invested Capital -61.71% 51% F 16% F
Return on Assets -40.15% 25% F 7% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 6.36 41% F 25% F
Short Percent 3.05% 73% C 50% F
Beta 1.70 39% F 22% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.